| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2019 | Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer | Liu Y.-N.; Tsai M.-F.; Wu S.-G.; Chang T.-H.; TZU-HSIU TSAI ; Gow C.-H.; Chang Y.-L.; Shih J.-Y. | International Journal of Cancer | 16 | 18 | |
| 2019 | Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer | Liu Y.-N.; Tsai M.-F.; Wu S.-G.; Chang T.-H.; Tsai T.-H.; Gow C.-H.; YIH-LEONG CHANG ; Shih J.-Y. | International Journal of Cancer | 14 | 18 | |
| 2019 | Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer | Liu Y.-N.; Tsai M.-F.; SHANG-GIN WU ; Chang T.-H.; Tsai T.-H.; Gow C.-H.; Chang Y.-L.; Shih J.-Y. | International Journal of Cancer | 3 | 18 | |
| 2019 | Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer | Liu Y.-N.; Tsai M.-F.; Wu S.-G.; Chang T.-H.; Tsai T.-H.; Gow C.-H.; Chang Y.-L.; JIN-YUAN SHIH | International Journal of Cancer | 3 | 18 | |
| 2017 | ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis | Chiu K.-L.; Lin Y.-S.; Kuo T.-T.; Lo C.-C.; Huang Y.-K.; Chang H.-F.; Chuang E.Y.; Lin C.-C.; Cheng W.-C.; Liu Y.-N.; LIANG-CHUAN LAI ; Sher Y.-P. | Oncotarget | 9 | 21 | |
| 2016 | Akt activation correlates with snail expression and potentially determines the recurrence of prostate cancer in patients at stage T2 after a radical prostatectomy | Chen W.-Y.; KUO-TAI HUA ; Lee W.-J.; Lin Y.-W.; Liu Y.-N.; Chen C.-L.; Wen Y.-C.; Chien M.-H. | International Journal of Molecular Sciences | 2 | ||
| 2009 | Antitumor agents 268. Design, synthesis, and mechanistic studies of new 9-substituted phenanthrene-based tylophorine analogues as potent cytotoxic agents | Yang X.; Shi Q.; Liu Y.-N.; Zhao G.; Bastow K.F.; Lin J.-C.; Yang S.-C.; PAN-CHYR YANG ; Lee K.-H. | Journal of Medicinal Chemistry | 38 | 38 | |
| 2016 | Association of BIM deletion polymorphism with intrinsic resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma | Wu S.-G.; Liu Y.-N.; Yu C.-J.; PAN-CHYR YANG ; Shih J.-Y. | JAMA Oncology | 18 | 14 | |
| 2016 | Association of BIM deletion polymorphism with intrinsic resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma | SHANG-GIN WU ; Liu Y.-N.; Yu C.-J.; Yang P.-C.; Shih J.-Y. | JAMA Oncology | 11 | 14 | |
| 2016 | Association of BIM deletion polymorphism with intrinsic resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma | Wu S.-G.; Liu Y.-N.; Yu C.-J.; Yang P.-C.; JIN-YUAN SHIH | JAMA Oncology | 11 | 14 | |
| 2016 | Association of BIM deletion polymorphism with intrinsic resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma | Wu S.-G.; Liu Y.-N.; CHONG-JEN YU ; Yang P.-C.; Shih J.-Y. | JAMA Oncology | 14 | ||
| 2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; YIH-LEONG CHANG ; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. | Oncologist | 8 | 9 | |
| 2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; JIH-HSIANG LEE ; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. | Oncologist | 8 | 9 | |
| 2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; TZU-HSIU TSAI ; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. | Oncologist | 8 | 8 | |
| 2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; CHEN-TU WU ; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. | Oncologist | 8 | 9 | |
| 2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | Yang C.-Y.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. | Oncologist | 8 | 9 | |
| 2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | Yang C.-Y.; WEI-YU LIAO ; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. | Oncologist | 8 | 9 | |
| 2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | Yang C.-Y.; Liao W.-Y.; Ho C.-C.; KUAN-YU CHEN ; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. | Oncologist | 8 | 9 | |
| 2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; CHIA-LIN HSU ; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. | Oncologist | 8 | 8 | |
| 2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; BIN-CHI LIAO ; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. | Oncologist | 9 |
